- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07590011
Effects of Four-Cell Galvanic Therapy on Pain and Balance in Diabetic Peripheral Neuropathy (GABATH-DPN)
Effects of Four-Cell Galvanic Bath Therapy on Pain and Balance in Patients With Diabetic Distal Symmetric Polyneuropathy: A Prospective, Randomized, Controlled, Single-Blind Study
연구 개요
상태
상세 설명
Diabetic distal symmetric polyneuropathy (DSPN) is one of the most prevalent chronic complications of diabetes mellitus and is characterized by progressive peripheral nerve damage, leading to symptoms such as distal sensory loss, neuropathic pain, and impaired proprioception. These alterations negatively affect postural control mechanisms, resulting in balance impairment, increased risk of falls, and reduced functional independence. As a consequence, DSPN significantly decreases quality of life and poses an important clinical and socioeconomic burden.
Conventional rehabilitation programs, including range of motion, strengthening, balance, coordination, and endurance exercises, are commonly used in the management of DSPN. However, despite these interventions, persistent neuropathic pain and balance deficits often remain inadequately controlled. Therefore, there is a growing interest in adjunctive therapeutic approaches that target both sensory and motor components of postural control.
Electrical stimulation modalities have been proposed as potential therapeutic options due to their ability to modulate peripheral nerve excitability and enhance somatosensory feedback. Four-cell galvanic bath therapy is a non-invasive intervention that applies low-intensity direct current through water-filled electrodes to the upper and lower extremities. This method may stimulate cutaneous receptors and peripheral nerve endings, increase afferent sensory input, and facilitate neuromuscular activation. Through these mechanisms, galvanic bath therapy may contribute to improved postural stability and reduction of neuropathic pain. However, current evidence regarding its combined effects on both pain and balance in patients with DSPN is limited, highlighting the need for well-designed clinical trials.
This study was designed as a prospective, randomized, controlled, single-blind clinical trial including patients aged 40-75 years diagnosed with DSPN. Participants were randomly assigned in a 1:1 ratio to either an intervention group receiving four-cell galvanic bath therapy in addition to conventional rehabilitation or a control group receiving only conventional rehabilitation. The rehabilitation program consisted of standardized exercises including range of motion, stretching, strengthening, balance, coordination, and endurance training, and was applied for 4 weeks, three sessions per week, with each session lasting approximately one hour.
In the intervention group, four-cell galvanic bath therapy was administered concurrently with the conventional rehabilitation program. The application was performed using a standardized protocol to ensure consistency across participants. Outcome measures were assessed at baseline and after the intervention period using validated clinical assessment tools. Pain intensity and balance performance were evaluated as primary outcomes, while additional functional and quality of life parameters were assessed as secondary outcomes.
The primary objective of this study is to investigate the effectiveness of four-cell galvanic bath therapy on reducing pain and improving balance in patients with DSPN. A secondary objective is to explore whether enhanced somatosensory input through electrical stimulation contributes to improved postural control and functional outcomes. The findings of this study are expected to provide clinically relevant evidence regarding the role of galvanic bath therapy as an adjunctive treatment modality in the rehabilitation of patients with diabetic peripheral neuropathy.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Ankara, 터키 (Türkiye)
- Ankara Etlik City Hospital Physical Medicine and Rehabilitation Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Diagnosis of type 2 diabetes mellitus
- Confirmed diagnosis of diabetic distal symmetric polyneuropathy according to the 2009 Toronto Consensus criteria
- Age between 40 and 75 years
- Adequate cognitive function to understand and respond to questionnaires and follow instructions (Mini-Mental State Examination score ≥ 24)
- No initiation or dosage change in neuropathic pain medication within the last 1 month
- Sufficient functional mobility to participate in the assessment and treatment protocol (ability to stand independently or with minimal assistance)
Exclusion Criteria:
- Presence of lower extremity amputation
- Active diabetic foot ulcer, significant skin integrity impairment, or open wound in the treatment area
- Cognitive impairment (MMSE < 24) or communication problems interfering with assessments
- Presence of orthopedic, musculoskeletal, or peripheral conditions affecting balance
- Medical instability
- Use of medications affecting balance or cognitive function
- Use of assistive devices
- Severe musculoskeletal disorders
- Initiation or dosage change of neuropathic pain medication within the last 1 month
- Presence of Charcot neuroarthropathy
- Polyneuropathy due to causes other than diabetes
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Four-Cell Galvanic Bath Therapy + Conventional Rehabilitation
Participants received four-cell galvanic bath therapy in addition to a conventional rehabilitation program.
The rehabilitation program included range of motion, stretching, strengthening, balance, coordination, and endurance exercises.
The intervention was applied for 4 weeks, three sessions per week, with each session lasting approximately one hour.
|
Four-cell galvanic bath therapy was applied using a direct current (1.5 mA) delivered through water-filled electrodes to both upper and lower extremities for 20 minutes per session, three times per week for 4 weeks.
다른 이름들:
A standardized rehabilitation program including range of motion, stretching, strengthening, balance, coordination, and endurance exercises, performed 3 times per week for 4 weeks, with each session lasting approximately 60 minutes.
|
|
활성 비교기: Conventional Rehabilitation Alone
Participants received a conventional rehabilitation program consisting of range of motion, stretching, strengthening, balance, coordination, and endurance exercises.
The program was applied for 4 weeks, three sessions per week, with each session lasting approximately one hour.
|
A standardized rehabilitation program including range of motion, stretching, strengthening, balance, coordination, and endurance exercises, performed 3 times per week for 4 weeks, with each session lasting approximately 60 minutes.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Postural Stability (Stability Index) Measured by TecnoBody Prokin PK252
기간: Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
|
Postural stability will be assessed using the TecnoBody Prokin PK252 device.
The Stability Index parameter reflects postural sway based on center of pressure displacement.
Higher values indicate poorer balance performance and reduced postural stability.
|
Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Berg Balance Scale (BBS)
기간: Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
|
Balance performance will be assessed using the Berg Balance Scale (BBS).
The BBS is a 14-item clinical balance assessment scale with a total score ranging from 0 to 56.
Higher scores indicate better balance performance and lower fall risk.
Assessments will be performed at baseline, post-treatment, and follow-up, and scores will be compared between groups.
|
Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
|
|
Functional Reach Test (FRT)
기간: Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
|
Dynamic balance will be assessed using the Functional Reach Test (FRT).
The maximal forward reach distance will be measured in centimeters while maintaining a fixed standing position without stepping.
Greater reach distance indicates better dynamic balance and postural control, whereas shorter reach distance indicates impaired balance performance and increased fall risk.
Assessments will be performed at baseline, post-treatment, and follow-up.
|
Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
|
|
Timed Up and Go Test (TUG)
기간: Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
|
Functional mobility will be assessed using the Timed Up and Go (TUG) test.
Participants will stand up from a chair, walk 3 meters, turn around, walk back, and sit down again.
Completion time will be recorded in seconds.
Shorter completion time indicates better functional mobility and balance performance, whereas longer completion time indicates impaired mobility and balance.
Assessments will be performed at baseline, post-treatment, and follow-up.
|
Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
|
|
Single Leg Stance Test
기간: Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
|
Static balance will be assessed using the Single Leg Stance Test.
Participants will be instructed to stand on one leg without external support for as long as possible.
Standing duration will be recorded in seconds.
Longer standing duration indicates better static balance and postural stability, whereas shorter duration indicates impaired balance performance.
Assessments will be performed at baseline, post-treatment, and follow-up.
|
Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
|
|
Short-Form McGill Pain Questionnaire (SF-MPQ)
기간: Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
|
Pain severity will be assessed using the Short-Form McGill Pain Questionnaire (SF-MPQ).
Higher total scores indicate greater pain severity.
Assessments will be performed at baseline, post-treatment, and follow-up.
|
Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
|
|
Physical Component Summary of SF-12 (PCS-12)
기간: Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
|
Physical health status will be assessed using the Physical Component Summary (PCS-12) score of the Short Form-12 Health Survey.
Scores range from 0 to 100, with higher scores indicating better physical health status.
|
Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
|
|
Mental Component Summary of SF-12 (MCS-12)
기간: Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
|
Mental health status will be assessed using the Mental Component Summary (MCS-12) score of the Short Form-12 Health Survey.
Scores range from 0 to 100, with higher scores indicating better mental health status.
|
Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- AEŞH-EK1-2025-057
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .